Digsu N Koye1, Joanna Ling1,2, John Dibato1, Kamlesh Khunti3, Olga Montvida1, Sanjoy K Paul4. 1. Melbourne EpiCentre, University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia. 2. School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia. 3. Department of Health Sciences, University of Leicester, Leicester, U.K. 4. Melbourne EpiCentre, University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia sanjoy.paul@unimelb.edu.au.
Abstract
OBJECTIVE: To evaluate temporal prevalence trend, cardiometabolic risk factors, and the risk of atherosclerotic cardiovascular disease (ASCVD) and all-cause mortality (ACM) in incident young- and usual-onset type 2 diabetes. RESEARCH DESIGN AND METHODS: From the U.K. primary care database, 370,854 people with a new diagnosis of type 2 diabetes from 2000 to 2017 were identified. Analyses were conducted by age-group (18-39, 40-49, 50-59, 60-69, 70-79 years) and high-/low-risk status without history of ASCVD at diagnosis, with subjects with two or more of current smoking, high systolic blood pressure, high LDL cholesterol (LDL-C), or chronic kidney disease classified as high risk. RESULTS: The proportion of people aged <50 years at diagnosis increased during 2000-2010 and then stabilized. The incidence rates of ASCVD and ACM declined in people aged ≥50 years but did not decrease in people <50 years. Compared with people aged ≥50 years, those aged 18-39 years at diagnosis had a higher proportion of obesity (71% obese) and higher HbA1c (8.6%), and 71% had high LDL-C, while only 18% were on cardioprotective therapy. Although 2% in this age-group had ASCVD at diagnosis, 23% were identified as high risk. In the 18-39-year age-group, the adjusted average years to ASCVD/ACM in high-risk individuals (9.1 years [95% CI 8.2-10.0]/9.3 years [8.1-10.4]) were similar to the years in those with low risk (10.0 years [9.5-10.5]/10.5 years [9.7-11.2]). However, individuals aged ≥50 years with high risk were likely to experience an ASCVD event 1.5-2 years earlier and death 1.1-1.5 years earlier compared with low-risk groups (P < 0.01). CONCLUSIONS: Unlike usual-onset, young-onset type 2 diabetes has similar cardiovascular and mortality risk irrespective of cardiometabolic risk factor status at diagnosis. The guidelines on the management of young-onset type 2 diabetes for intensive risk factor management and cardioprotective therapies need to be urgently reevaluated through prospective studies.
OBJECTIVE: To evaluate temporal prevalence trend, cardiometabolic risk factors, and the risk of atherosclerotic cardiovascular disease (ASCVD) and all-cause mortality (ACM) in incident young- and usual-onset type 2 diabetes. RESEARCH DESIGN AND METHODS: From the U.K. primary care database, 370,854 people with a new diagnosis of type 2 diabetes from 2000 to 2017 were identified. Analyses were conducted by age-group (18-39, 40-49, 50-59, 60-69, 70-79 years) and high-/low-risk status without history of ASCVD at diagnosis, with subjects with two or more of current smoking, high systolic blood pressure, high LDL cholesterol (LDL-C), or chronic kidney disease classified as high risk. RESULTS: The proportion of people aged <50 years at diagnosis increased during 2000-2010 and then stabilized. The incidence rates of ASCVD and ACM declined in people aged ≥50 years but did not decrease in people <50 years. Compared with people aged ≥50 years, those aged 18-39 years at diagnosis had a higher proportion of obesity (71% obese) and higher HbA1c (8.6%), and 71% had high LDL-C, while only 18% were on cardioprotective therapy. Although 2% in this age-group had ASCVD at diagnosis, 23% were identified as high risk. In the 18-39-year age-group, the adjusted average years to ASCVD/ACM in high-risk individuals (9.1 years [95% CI 8.2-10.0]/9.3 years [8.1-10.4]) were similar to the years in those with low risk (10.0 years [9.5-10.5]/10.5 years [9.7-11.2]). However, individuals aged ≥50 years with high risk were likely to experience an ASCVD event 1.5-2 years earlier and death 1.1-1.5 years earlier compared with low-risk groups (P < 0.01). CONCLUSIONS: Unlike usual-onset, young-onset type 2 diabetes has similar cardiovascular and mortality risk irrespective of cardiometabolic risk factor status at diagnosis. The guidelines on the management of young-onset type 2 diabetes for intensive risk factor management and cardioprotective therapies need to be urgently reevaluated through prospective studies.
Authors: John Dibato; Olga Montvida; Joanna Ling; Digsu Koye; William H Polonsky; Sanjoy K Paul Journal: Diabetologia Date: 2022-09-05 Impact factor: 10.460
Authors: Muthiah Vaduganathan; Silvio E Inzucchi; Naveed Sattar; David H Fitchett; Anne Pernille Ofstad; Martina Brueckmann; Jyothis T George; Subodh Verma; Michaela Mattheus; Christoph Wanner; Bernard Zinman; Javed Butler Journal: Diabetes Obes Metab Date: 2021-10-07 Impact factor: 6.408
Authors: Mary Ellen Vajravelu; Talia A Hitt; Sandra Amaral; Lorraine E Levitt Katz; Joyce M Lee; Andrea Kelly Journal: Pediatr Diabetes Date: 2021-06-30 Impact factor: 3.409
Authors: Guoshuai Shi; Ni Zhu; Lin Qiu; Hong Yan; Lingxia Zeng; Duolao Wang; Shaonong Dang; Zhaoqing Li; Yijun Kang; Tao Chen; Chao Li Journal: Int J Gen Med Date: 2021-10-12
Authors: Mary M Barker; Francesco Zaccardi; Emer M Brady; Gaurav S Gulsin; Andrew P Hall; Joseph Henson; Zin Zin Htike; Kamlesh Khunti; Gerald P McCann; Emma L Redman; David R Webb; Emma G Wilmot; Tom Yates; Jian Yeo; Melanie J Davies; Jack A Sargeant Journal: World J Diabetes Date: 2022-03-15
Authors: Shivani Misra; David Gable; Kamlesh Khunti; Emma Barron; Bob Young; Partha Kar; Jonathan Valabhji Journal: Diabet Med Date: 2022-08-23 Impact factor: 4.213